Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) EBITDA: 2022-2024

Historic EBITDA for Lexeo Therapeutics (LXEO) over the last 3 years, with Dec 2024 value amounting to -$98.4 million.

  • Lexeo Therapeutics' EBITDA rose 1.47% to -$15.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$68.5 million, marking a year-over-year change of. This contributed to the annual value of -$98.4 million for FY2024, which is 48.26% down from last year.
  • Latest data reveals that Lexeo Therapeutics reported EBITDA of -$98.4 million as of FY2024, which was down 48.26% from -$66.4 million recorded in FY2023.
  • In the past 5 years, Lexeo Therapeutics' EBITDA registered a high of -$60.5 million during FY2022, and its lowest value of -$98.4 million during FY2024.
  • In the last 3 years, Lexeo Therapeutics' EBITDA had a median value of -$66.4 million in 2023 and averaged -$75.1 million.
  • Data for Lexeo Therapeutics' EBITDA shows a maximum YoY slumped of 48.26% (in 2024) over the last 5 years.
  • Lexeo Therapeutics' EBITDA (Yearly) stood at -$60.5 million in 2022, then decreased by 9.73% to -$66.4 million in 2023, then tumbled by 48.26% to -$98.4 million in 2024.